Compare PTRN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTRN | STOK |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | PTRN | STOK |
|---|---|---|
| Price | $11.50 | $34.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.89 | ★ $36.10 |
| AVG Volume (30 Days) | ★ 834.7K | 586.4K |
| Earning Date | 01-01-0001 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $36,555,000.00 |
| Revenue This Year | $39.63 | $428.68 |
| Revenue Next Year | $24.32 | N/A |
| P/E Ratio | ★ N/A | $40.16 |
| Revenue Growth | N/A | ★ 316.34 |
| 52 Week Low | $9.19 | $5.35 |
| 52 Week High | $20.10 | $39.81 |
| Indicator | PTRN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 54.65 |
| Support Level | $11.21 | $30.50 |
| Resistance Level | $15.09 | $34.95 |
| Average True Range (ATR) | 0.75 | 2.24 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 88.17 | 43.02 |
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.